
CLAIMS

1. Compounds of the formula (I)



(I)

in which

	R1	denotes Y or -$(CY_2)_n$-Ar,
	R2	denotes Y, -$(CY_2)_p$-$(C[YR6])_s$-R7 or -alk-R7,
	R3	denotes Y or CN,
	R4	denotes Y, Hal, -$(CY_2)_p$-COOY or -$(CY_2)_p$-CO-NYY,
	R5	denotes A, Hal, -$(CY_2)_p$-OY, -$(CY_2)_p$-NYY, -$(CY_2)_p$-COOY, -$(CY_2)_p$-CO-NYY or -$(CY_2)_p$-NY-COY,
	R6	denotes Y, Hal, -$(CY_2)_n$-NYY, -$(CY_2)_n$-NY-COO-$(CY_2)_n$-SiA_3, -$(CY_2)_n$-COOY, -CO-NYY, -CO-NY-$(CY_2)_n$-OY, -CO-NY-$(CY_2)_n$-NYY or SO_2A,
	R7	denotes -$(CY_2)_p$-Ar or -$(CY_2)_p$-Het^1,
	X	denotes CH_2, O, S or a single bond,
	Y	denotes H or A,
	A	denotes unbranched or branched alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, where 1, 2, 3, 4, 5, 6 or 7 H atoms may be replaced, independently of one another, by Hal,
	Alk	denotes alkenyl having 1, 2, 3, 4, 5 or 6 C atoms, where 1, 2, 3 or 4 H atoms may be replaced, independently of one another, by Hal and/or OY,
	Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, CN, -$(CY_2)_p$-OY, -$(CY_2)_p$-NYY, -$(CY_2)_p$-COOY, -$(CY_2)_p$-CO-NYY or -$(CY_2)_p$-NY-COY,
	Het^1	denotes mono- or bicyclic heteroaryl having 2, 3, 4, 5, 6, 7, 8 or 9 C atoms and 1, 2, 3 or 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, CN, -$(CY_2)_p$-OY, -$(CY_2)_p$-NYY, -$(CY_2)_p$-COOY, -$(CY_2)_p$-CO-NYY, -$(CY_2)_p$-NY-COY or -SO_2-Het^2,

Het^2 denotes a monocyclic saturated heterocycle having 2, 3, 4, 5, 6 or 7 C atoms and 1, 2, 3 or 4 N, O and/or S atoms, which may be unsubstituted or monosubstituted by A,


Hal denotes F, Cl, Br or I,

m denotes 0, 1, 2, 3 or 4, and

n, p, s, independently of one another, denote 0, 1, 2, 3, 4, 5 or 6,

and/or physiologically acceptable salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1 having the sub-formula (IA)



(IA)

in which

R2 denotes Y or -$(CY_2)_p$-C(YR6)-R7,

R5 denotes Y or Hal,

R6 denotes Y, -$(CY_2)_n$-NYY, -CO-NYY or -CO-NY-$(CY_2)_n$-OY,

R7 denotes Ar or Het^1,

Y denotes H or A,

A denotes unbranched or branched alkyl having 1, 2, 3 or 4 C atoms, where 1, 2 or 3 H atoms may be replaced, independently of one another, by Hal,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal,

Het^1 denotes mono- or bicyclic heteroaryl having 2, 3, 4, 5, 6, 7, 8 or 9 C atoms and 1, 2 or 3 N and/or S atoms, which may be unsubstituted or mono- or disubstituted by Hal, A, OY or -SO_2-Het^2,


Het^2 denotes a monocyclic saturated heterocycle having 3, 4 or 5 C atoms and 1 or 2 N and/or O atoms,

Hal denotes F, Cl, Br or I, and

n, p, independently of one another, denote 0, 1, 2 or 3,

and/or physiologically acceptable salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 having the sub-formula (IB)




(IB)

in which

	R2	denotes R7, -alk-Ar or -alk-Het^1,
	R5	denotes Y or Hal,
	R7	denotes -$(CY_2)_p$-Ar or -$(CY_2)_p$-Het^1,
	Y	denotes H or A,
	A	denotes unbranched or branched alkyl having 1, 2, 3 or 4 C atoms, where 1, 2 or 3 H atoms may be replaced, independently of one another, by Hal,
	Alk	denotes alkenyl having 1, 2 or 3 C atoms, where 1 or 2 H atoms may be replaced by Hal and/or OH,
	Ar	denotes phenyl which is unsubstituted or mono- or disubstituted by Hal,
	Het^1	denotes mono- or bicyclic heteroaryl having 2, 3, 4, 5, 6, 7, 8 or 9 C atoms and 1, 2 or 3 N and/or S atoms, which may be unsubstituted or mono- or disubstituted by Hal, A, OY or -SO_2-Het^2,
	Het^2	denotes a monocyclic saturated heterocycle having 3, 4 or 5 C atoms and 1 or 2 N and/or O atoms,
	Hal	denotes F, Cl, Br or I, and
	p	denotes 0, 1, 2 or 3,

and/or physiologically acceptable salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to Claim 3 having the sub-formula (IB-1)




(IB-1)





in which



R2	denotes	R7, -alk-Ar or -alk-Het[1],
R5	denotes	Hal,
R7	denotes	Ar or Het[1],
A	denotes	unbranched or branched alkyl having 1, 2, 3 or 4 C atoms, where 1, 2 or 3 H atoms may be replaced, independently of one another, by Hal,
Alk	denotes	alkenyl having 1 or 2 C atoms,
Ar	denotes	phenyl which is unsubstituted or monosubstituted by Hal,
Het[1]	denotes	mono- or bicyclic heteroaryl having 2, 3, 4, 5, 6, 7, 8 or 9 C atoms and 1, 2 or 3 N and/or S atoms, which may be unsubstituted or mono- or disubstituted by Hal or A or, and
Hal	denotes	F, Cl, Br or I,





and/or physiologically acceptable salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios.





5. Compounds according to one of Claims 1 to 4, selected from the group:





1	




2	
3	
4	
5	





6	
7	





10	
11	
12	
13	





14	
15	
16	
17	





18	
19	
20	
21	




22	
23	
24	

25	
26	
27	
28	

29	
30	
31	
32	


33	
34	
35	
36	

37	
38	
39	
40	

41	
42	
43	

and/or physiologically acceptable salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios.

6. Intermediate compounds of the formula (II)



(II)

in which

R8 denotes NO_2 or NYY, and

R1, R2, R3, R5, Y and m have the meaning indicated in Claim 1,

and/or salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios.

7. Intermediate compounds according to Claim 6 in which

R1 denotes A,

R2 denotes A or $-(CH_2)_p-(CH_2)_s-Ar$,

R3 denotes CN,

R5 denotes Hal,

R8 denotes NH_2,

A denotes unbranched or branched alkyl having 1, 2, 3 or 4 C atoms, where 1, 2 or 3 H atoms may be replaced, independently of one another, by Hal,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal,


Hal denotes F, Cl, Br or I, and

m, p, s, independently of one another, denote 0, 1 or 2,

and/or salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios.

8. Process for the preparation of compounds of the formula (I) under Claim 1, sub-formulae thereof and/or physiologically acceptable salts, tautomers and/or stereo-isomers thereof, including mixtures thereof in all ratios, having the following steps:

(a) reaction of a compound of the formula (II)




(II)

in which R1, R2, R3, R5, R8 and m have the meaning indicated in Claim 7,

with a carboxylic acid halide and with an organic base in a solvent,

to give compounds of the sub-formula (IC)




(IC)

in which R1, R2, R3, R5 and m have the meaning indicated in Claim 7,

and optionally


(b') reaction of the compounds of the sub-formula (IC) with a compound Hal-R4,
in which R4 and Hal have the meaning indicated in Claim 1,
to give compounds of the sub-formula (ID)



(ID)

in which R1, R2, R3, R5 and m have the meaning indicated in Claim 7, and R4 has the meaning indicated in Claim 1,

(b'') conversion of R1, -O-R2, R3, R4 and/or R5 of the compounds of the sub-formula (ID) and/or addition of at least one R5 having the meaning indicated in Claim 1 to the phenyl ring of the compounds of the sub-formula (ID) to give compounds of the formula (I)



(I)


in which R1, R2, R3, R4, R5, X and m have the meaning indicated in Claim 1,

and/or

(b''') conversion of a base or acid of the compounds of the formula (I) or sub-formulae (IC) or (ID) into one of its physiologically acceptable salts.

9. Process for the preparation of intermediate compounds of the formula (II) according to Claim 6 and/or salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios, having the following steps:

(a) reaction of a compound of the formula (III)




(III)

in which

Hal denotes F, Cl, Br or I, and

R1, R2 and R8 have the meaning indicated in Claim 6,


with a compound of the formula (IV)



(IV)

in which R3, R5 and m have the meaning indicated in Claim 6,

to give compounds of the formula (II)



(II)

in which R1, R2, R3, R5, R8 and m have the meaning indicated in Claim 6,

and optionally

(b) conversion of a base or acid of the compounds of the formula (II) into one of its salts.

10. Use of compounds according to one of Claims 1 to 5 and/or physiologically acceptable salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios, for the inhibition of serine/threonine protein kinases in vitro, preferably PIKK and/or ATM, particularly preferably DNA-PK.

11. Use of at least one compound according to one of Claims 1 to 5 and/or physiologically acceptable salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios, for the sensitisation of cancer cells to an anticancer agent and/or

ionising radiation, with the proviso that the sensitisation does not take place in vivo on the human or animal body.

12. Medicaments comprising at least one compound according to one of Claims 1 to 5 and/or physiologically acceptable salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios.


13. Pharmaceutical composition comprising, as active compound, an effective amount of at least one compound according to one of Claims 1 to 5 and/or physiologically acceptable salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios, together with pharmaceutically tolerated assistants, in combination with at least one anticancer agent.

14. Compounds according to one of Claims 1 to 5 and/or physiologically acceptable salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios, for use in the prophylaxis, therapy and/or progress control of cancer, tumours, metastases and/or angiogenesis disorders, in combination with radiotherapy and/or with at least one anticancer agent.

15. Compounds according to one of Claims 1 to 5 and/or physiologically acceptable salts, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios, for use for the sensitisation of cancer cells to an anticancer agent and/or ionising radiation.

CLAIMS

1. A compound of the formula (I)



(I)

in which

R1	denotes Y or -$(CY_2)_n$-Ar,
R2	denotes Y, -$(CY_2)_p$-(C[YR6])$_s$-R7 or -alk-R7
R3	denotes Y or CN,
R4	denotes Y, Hal, -$(CY_2)_p$-COOY or -$(CY_2)_p$-CO-NYY,
R5	denotes A, Hal, -$(CY_2)_p$-OY, -$(CY_2)_p$-NYY, -$(CY_2)_p$-COOY, -$(CY_2)_p$-CO-NYY or -$(CY_2)_p$-NY-COY,
R6	denotes Y, Hal, -$(CY_2)_n$-NYY, -$(CY_2)_n$-NY-COO-$(CY_2)_n$-SiA_3, -$(CY_2)_n$-COOY, -CO-NYY, -CO-NY-$(CY_2)_n$-OY, -CO-NY-$(CY_2)_n$-NYY or SO_2A,
R7	denotes -$(CY_2)_p$-Ar, -$(CY_2)_p$-Het^1,
X	denotes CH_2, O, S or a single bond,
Y	denotes H or A,
A	denotes unbranched or branched alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, where 1, 2, 3, 4, 5, 6 or 7 H atoms may be replaced, independently of one another, by Hal,
Alk	denotes alkenyl having 1, 2, 3, 4, 5 or 6 C atoms, where 1, 2, 3 or 4 H atoms may be replaced independently of one another, by Hal and/or OY,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, CN, -$(CY_2)_p$-OY, -$(CY_2)_p$-NYY, -$(CY_2)_p$-COOY, -$(CY_2)_p$-CO-NYY or -$(CY_2)_p$-NY-COY,
Het^1	denotes mono- or bicyclic heteroaryl having 2, 3, 4, 5, 6, 7, 8 or 9 C atoms and 1, 2, 3 or 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, CN, -$(CY_2)_p$-OY, -$(CY_2)_p$-NYY, -

$(CY_2)_p$-COOY, -$(CY_2)_p$-CO-NYY, -$(CY_2)_p$-NY-COY or $-SO_2$-Het^2,

Het^2 denotes a monocyclic saturated heterocycle having 2, 3, 4, 5, 6 or 7 C atoms and 1, 2, 3 or 4 N, O and/or S atoms, which may be unsubstituted or monosubstituted by A,


Hal denotes F, Cl, Br or I,

m denotes 0, 1, 2, 3 or 4, and

n, p, s, independently of one another, denote 0, 1, 2, 3, 4, 5 or 6,

and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio.

2. The compound according to Claim 1 having the sub-formula (IA)



(IA)

in which

R2 denotes Y or -$(CY_2)_p$-C(YR6)-R7,

R5 denotes Y or Hal,

R6 denotes Y, -$(CY_2)_n$-NYY, -CO-NYY or -CO-NY-$(CY_2)_n$-OY,

R7 denotes Ar or Het^1,

Y denotes H or A,

A denotes unbranched or branched alkyl having 1, 2, 3 or 4 C atoms, where 1, 2 or 3 H atoms may be replaced, independently of one another, by Hal,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal,

Het^1 denotes mono- or bicyclic heteroaryl having 2, 3, 4, 5, 6, 7, 8 or 9 C atoms and 1, 2 or 3 N and/or S atoms, which may be unsubstituted or mono- or disubstituted by Hal, A, OY or $-SO_2$-Het^2,


Het^2 denotes a monocyclic saturated heterocycle having 3, 4 or 5 C atoms and 1 or 2 N and/or O atoms,

Hal denotes F, Cl, Br or I, and

n, p, independently of one another, denote 0, 1, 2 or 3,

and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio.

3. A compound according to Claim 1 having the sub-formula (IB)




(IB)

in which

R2	denotes R7, -alk-Ar or -alk-Het^1,
R5	denotes Y or Hal,
R7	denotes -$(CY_2)_p$-Ar, or -$(CY_2)_p$- Het^1,
Y	denotes H or A,
A	denotes unbranched or branched alkyl having 1, 2, 3 or 4 C atoms, where 1, 2 or 3 H atoms may be replaced, independently of one another, by Hal,
Alk	denotes alkenyl having 1, 2 or 3 C atoms, where 1 or 2 H atoms may be replaced by Hal and/or OH,
Ar	denotes phenyl which is unsubstituted or mono- or disubstituted by Hal,
Het^1	denotes mono- or bicyclic heteroaryl having 2, 3, 4, 5, 6, 7, 8 or 9 C atoms and 1, 2 or 3 N and/or S atoms, which may be unsubstituted or mono- or disubstituted by Hal, A, OY or –SO_2-Het^2,
Het^2	denotes a monocyclic saturated heterocycle having 3, 4 or 5 C atoms and 1 or 2 N and/or O atoms,
Hal	denotes F, Cl, Br or I, and
p	denotes 0, 1, 2 or 3,

and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio.

4. A compound according to Claim 3 having the sub-formula (IB-1)



(IB-1)

in which

R2 denotes R7, -alk-Ar or -alk-Het[1],

R5 denotes Hal,

R7 denotes Ar or Het[1],

A denotes unbranched or branched alkyl having 1, 2, 3 or 4 C atoms, where 1, 2 or 3 H atoms may be replaced, independently of one another, by Hal,

Alk denotes alkenyl having 1 or 2 C atoms,


Ar denotes phenyl which is unsubstituted or monosubstituted by Hal,





Het[1] denotes mono- or bicyclic heteroaryl having 2, 3, 4, 5, 6, 7, 8 or 9 C atoms and 1, 2 or 3 N and/or S atoms, which may be unsubstituted or mono- or disubstituted by Hal or A or, and





Hal denotes F, Cl, Br or I,





and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio.





5. A compound according to any one of Claims 1 to 4, selected from the group:





1	




2	
3	
4	
5	





6	
7	
8	
9	





10	
11	
12	
13	





14	
15	
16	
17	





18	
19	
20	
21	




22	
23	
24	

25	
26	
27	
28	

29	
30	
31	
32	


33	
34	
35	
36	

37	
38	
39	
40	

41	
42	
43	

and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio.

6. A compound of the formula (II)



(II)

in which

R8 denotes NO_2 or NYY,

R3 denotes CN, and

R1, R2, R5, Y and m having the meaning indicated in Claim 1,

and/or a salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio.

7. The compound according to Claim 6 in which

R1 denotes A,

R2 denotes A or $-(CY_2)_p-(CY_2)_s-Ar$,

R3 denotes CN,

R5 denotes Hal,

R8 denotes NH_2,

A denotes unbranched or branched alkyl having 1, 2, 3 or 4 C atoms, where 1, 2 or 3 H atoms may be replaced, independently of one another, by Hal,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal,


Hal denotes F, Cl, Br or I, and

m, p, s, independently of one another, denote 0, 1 or 2,

and/or a salt, tautomer, and/or stereoisomer thereof, including a mixture thereof in any ratio.

8. Process for the preparation of a compound of the formula (I) under Claim 1, a sub-formula thereof and/or a physiologically acceptable salt, tautomer and/or stereo-isomer thereof, including a mixture thereof in any ratio, having the following steps:

(a) reaction of a compound of the formula (II)




(II)

in which R1, R2, R3, R5, R8 and m have the meaning indicated in Claim 7,

with a carboxylic acid halide and with an organic base in a solvent,

to give a compound of the sub-formula (IC)




(IC)

in which R1, R2, R3, R5 and m have the meaning indicated in Claim 7,

and optionally


(b') reaction of the compound of the sub-formula (IC) with a compound Hal-R4, in which R4 and Hal have the meaning indicated in Claim 1, to give a compound of the sub-formula (ID)



(ID)

in which R1, R2, R3, R5 and m have the meaning indicated in Claim 7, and R4 has the meaning indicated in Claim 1,

(b") conversion of R1, -O-R2, R3, R4 and/or R5 of the compound of the sub-formula (ID) and/or addition of at least one R5 having the meaning indicated in Claim 1 to the phenyl ring of the compound of the sub-formula (ID) to give the compound of the formula (I)



(I)


in which R1, R2, R3, R4, R5, X and m have the meaning indicated in Claim 1,

and/or

(b"') conversion of a base or acid of the compound of the formula (I) or sub-formulae (IC) or (ID) into one of its physiologically acceptable salts.

9. Process for the preparation of a compound of the formula (II) according to Claim 6 and/or a salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio, having the following steps:

(a) reaction of a compound of the formula (III)




(III)

in which

Hal denotes F, Cl, Br or I, and

R1, R2 and R8 have the meaning indicated in Claim 6,


with a compound of the formula (IV)



(IV)

in which R3, R5 and m have the meaning indicated in Claim 6,

to give a compound of the formula (II)



(II)

in which R1, R2, R3, R5, R8 and m have the meaning indicated in Claim 6,

and optionally

(b) conversion of a base or acid of the compound of the formula (II) into one of its salts.

10. Use of the compound according to any one of Claims 1 to 5 and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio, for the inhibition of a serine/threonine protein kinase in vitro.

11. The use of Claim 10, wherein the serine/threonine protein kinase is a PIKK.

12. The use of Claim 10 or 11, wherein the serine/threonine protein kinase is DNA-PK or ATM.

13. Use of at least one compound according to any one of Claims 1 to 5 and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio, for the sensitisation of cancer cells to an anticancer agent and/or ionising radiation.

14. A medicament comprising at least one compound according to any one of Claims 1 to 5 and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio.

15. Pharmaceutical composition comprising, as active compound, an effective amount of at least one compound according to any one of Claims 1 to 5 and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio, together with one or more pharmaceutically tolerated assistants, in combination with at least one anticancer agent.

16. The compound according to any one of Claims 1 to 5 and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio, for use in the prophylaxis, therapy and/or progress control of cancer, a tumour, metastases and/or an angiogenesis disorder, in combination with radiotherapy and/or with at least one anticancer agent.

17. The compound according to any one of Claims 1 to 5 and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio, for use for the sensitisation of cancer cells to an anticancer agent and/or ionising radiation.

18. Use of a compound according to any one of Claims 1 to 5 and/or a physiologically acceptable salt, tautomer and/or stereoisomer thereof, including a mixture thereof in any ratio, for the preparation of a medicament for

- the prophylaxis therapy and/or progress control of cancer, a tumour, metastases and/or an angiogenesis disorder; or
- the sensitisation of cancer cells to an anticancer agent and/or ionising radiation.